Recro Pharma

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. Our lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo controlled trial demonstrating pain relief. We have studied various dosage forms of Dex in eight completed clinical studies, two of which were placebo controlled trials that demonstrated meaningful pain relief. As our product candidates are not opioid based drugs, we expect to overcome many of the side effects associated with commonly prescribed opioid based therapeutics, including addiction, constipation and respiratory distress while maintaining analgesic, or pain relieving, effect. We are ready to begin a Phase IIb trial with Dex in patients experiencing post-operative pain. We believe Dex will become an alternative pain medication to opioids for the more than 50 million surgical procedures that require post-operative pain medication. If approved, Dex would also be the first and only approved post-operative pain drug in its class of drugs.
Type
Public
HQ
Malvern, US
Size (employees)
186 (est)
Recro Pharma is headquartered in Malvern, US

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd

Recro Pharma Metrics

Recro Pharma Financial Metrics

Revenue (2015)

$52 m

Net income (2015)

$3 m

Market capitalization (21-Mar-2017)

$151.8 m

Closing share price (21-Mar-2017)

$8
Recro Pharma's current market capitalization is $151.8 m.
Recro Pharma's revenue was reported to be $52 m in FY, 2015
FY, 2015

Revenue

$52 m

Net Income

$3 m

Recro Pharma Market Value History

Recro Pharma News

Recro Pharma Company Life

You may also be interested in